Published in Arch Neurol on October 01, 1974
Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann N Y Acad Sci (2008) 1.85
Neuropathological changes caused by hydrocephalus. Acta Neuropathol (1993) 1.73
Clinical diagnosis of Binswanger's disease. J Neurol Neurosurg Psychiatry (1990) 1.63
Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry (1995) 1.41
Three decades of normal pressure hydrocephalus: are we wiser now? J Neurol Neurosurg Psychiatry (1994) 1.39
Subcortical arteriosclerotic encephalopathy: a clinical and radiological investigation. J Neurol Neurosurg Psychiatry (1981) 1.36
Recognition and management of lacunar strokes. Br Med J (Clin Res Ed) (1983) 1.07
Syndrome of normal pressure hydrocephalus: possible relation to hypertensive and arteriosclerotic vasculopathy. J Neurol Neurosurg Psychiatry (1977) 1.07
Adult idiopathic communicating hydrocephalus with and without shunting. J Neurol Neurosurg Psychiatry (1978) 1.06
Non-tumoural aqueduct stenosis and normal pressure hydrocephalus in the elderly. J Neurol Neurosurg Psychiatry (1986) 0.93
Risk factors for the syndrome of ventricular enlargement with gait apraxia (idiopathic normal pressure hydrocephalus): a case-control study. J Neurol Neurosurg Psychiatry (1989) 0.92
Recovery in hydrocephalic dementia after shunt operation. J Neurol Neurosurg Psychiatry (1978) 0.88
Increased prevalence of cardiovascular disease in idiopathic normal pressure hydrocephalus patients compared to a population-based cohort from the HUNT3 survey. Fluids Barriers CNS (2014) 0.82
Normal pressure hydrocephalus. Br Med J (Clin Res Ed) (1986) 0.75
Cardiovascular risk factors in Chiari malformation and idiopathic intracranial hypertension. Brain Behav (2017) 0.75
Cardiac output in idiopathic normal pressure hydrocephalus: association with arterial blood pressure and intracranial pressure wave amplitudes and outcome of shunt surgery. Fluids Barriers CNS (2011) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 6.03
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet (1997) 5.39
Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol (1984) 5.21
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology (1988) 4.28
Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell (1988) 3.57
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry (1980) 3.19
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
Wish to die in end-stage ALS. Neurology (2005) 2.97
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. Neuroepidemiology (1997) 2.96
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol (1996) 2.86
Inclusion body myositis and myopathies. Ann Neurol (1995) 2.68
Primary lateral sclerosis. A clinical diagnosis reemerges. Arch Neurol (1988) 2.62
Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology (2009) 2.60
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology (2007) 2.41
The DYT1 phenotype and guidelines for diagnostic testing. Neurology (2000) 2.39
Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med (1992) 2.34
The natural history of primary lateral sclerosis. Neurology (2006) 2.31
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology (2012) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
Premorbid weight, body mass, and varsity athletics in ALS. Neurology (2002) 2.23
Idiopathic cervical dystonia: clinical characteristics. Mov Disord (1991) 2.21
Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord (1992) 2.15
Accuracy of family history data on Parkinson's disease. Neurology (2003) 2.15
Functional brain networks in DYT1 dystonia. Ann Neurol (1998) 2.14
Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology (1992) 2.14
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology (2004) 2.09
Oral and genital tardive pain syndromes. Neurology (1994) 2.07
Pentoxifylline in acute nonhemorrhagic stroke. A randomized, placebo-controlled double-blind trial. Stroke (1988) 2.05
What is it? Case 3, 1991: moaning in a man with parkinsonian signs. Mov Disord (1991) 2.05
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Distant effects of local injection of botulinum toxin. Muscle Nerve (1987) 2.02
Motor blocks in Parkinson's disease. Neurology (1992) 2.01
Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol (1989) 2.00
Complications of intravenous immune globulin treatment in neurologic disease. Neurology (1996) 1.97
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology (1994) 1.97
Myoglobinuria. Med Clin North Am (1972) 1.95
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Lumping or splitting? "Ophthalmoplegia-plus" or Kearns-Sayre syndrome? Ann Neurol (1977) 1.90
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord (1994) 1.88
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem (1966) 1.86
Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol (2000) 1.82
Prevalence of depressive disorders and change over time in late-stage ALS. Neurology (2005) 1.80
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci (1992) 1.79
Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet (1993) 1.78
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 1.77
Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell? N Engl J Med (1994) 1.73
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
A prospective study of preferences and actual treatment choices in ALS. Neurology (1999) 1.71
Cramps. N Engl J Med (1971) 1.67
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Delayed-onset cerebellar syndrome. Arch Neurol (1996) 1.65
"Maximal" thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg (1988) 1.63
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology (2007) 1.63
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. J Biol Chem (1966) 1.62
Chronic manganese intoxication. Arch Neurol (1974) 1.61
Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology (1990) 1.61
Muscular dystrophy in young girls. Neurology (1970) 1.60
Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol (1991) 1.60
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology (1998) 1.60
Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology (2010) 1.57
Lymphoproliferative disorders and motor neuron disease: an update. Neurology (1997) 1.54
Muscle phosphofructokinase deficiency. Arch Neurol (1967) 1.54
Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med (1980) 1.54
Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab (1993) 1.52
High dosage anticholinergic therapy in dystonia. Neurology (1983) 1.52
Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry (1998) 1.52
Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol (1995) 1.51
Laserlight cues for gait freezing in Parkinson's disease: an open-label study. Parkinsonism Relat Disord (2010) 1.51
Polyglucosan body disease. Muscle Nerve (1991) 1.50
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain (1998) 1.50
Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis. Is the tRNA(Leu(UUR)) gene an etiologic hot spot? J Clin Invest (1993) 1.48
Drugs, coma, and myoglobinuria. Arch Neurol (1972) 1.47
Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology (1991) 1.46
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology (1981) 1.46
The clinical spectrum of posthypoxic myoclonus. Mov Disord (2000) 1.46
Movement disorder in reflex sympathetic dystrophy: a case proven to be psychogenic by surveillance video monitoring. Mov Disord (1997) 1.45
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology (1974) 1.44
Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology (1979) 1.43
Grand mal seizures temporally related to cocaine use: clinical and diagnostic features. Ann Emerg Med (1992) 1.43
Emery-Dreifuss muscular dystrophy. Ann Neurol (1979) 1.42
The ALSFRSr predicts survival time in an ALS clinic population. Neurology (2005) 1.42
Welcome news about levodopa, but uncertainty remains. Ann Neurol (1998) 1.42
ALS defeats gabapentin: reflections on another failed treatment. Neurology (2001) 1.41
Regional distribution of gamma-aminobutyric acid (GABA) in brain of the rhesus monkey. J Neurochem (1968) 1.41
Tourette syndrome. Arch Neurol (1996) 1.39
Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology (1991) 1.39
Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology (1986) 1.38
Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology (1997) 1.36